Disclosed are 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives of Formula 1, stereoisomers and salts thereof, and methods for their preparation. Specific examples of compounds of formula 1 include: N-{ [7-(methylsulfonyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl} -propan-1-amine; 2-Methyl-N-{ [(2R)-7-(methylsulfonyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl} propan-1-amine, 2-Methyl-N-{ [7-(methylsulfony)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl} propan-1-amine, and N-{ [(2S)-5-Chloro-7-(methylsulfonyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl} -N-propylpropan-1amine. Compounds of formula 1 are useful for treating diseases, disorders or conditions responsive to modulation of dopaminergic function in the central nervous system, such as movement disorders, Parkinson's disease, Parkinsonism, dyskinesias, L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington's disease, iatrogenic psychoses and hallucinoses, non-iatrogenic psychoses and hallucinoses, schizophrenia, schizophreniform disorders, bipolar disorder, mood disorders, anxiety disorders, depression, obsessive-compulsive disease, neurodevelopmental disorders, Autism spectrum disorders, ADHD, Cerebral Palsy, Gilles de la Tourette's syndrome, neurodegenerative disorders, dementia, age-related cognitive impairment, sleep disorders, sexual disorders, eating disorders, obesitas, headaches, pains in conditions characterized by increased muscular tone, substance abuse, Alzheimer's disease or dementia disorders related to Alzheimer's disease.
1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives for the modulation of dopaminergic function in the central nervous system